This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
ARFGAP3 / ADP-ribosylation factor GTPase-activating protein 3 · IHC design guide
Design Immunohistochemistry for ARFGAP3
Plan ARFGAP3 chromogenic IHC in paraffin sections using cytoplasmic staining in glandular cells as the tissue reference (HPA tissue IHC). Compare staining cautiously with RNA data because their reported consistency is low (HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
ARFGAP3 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Cytoplasmic tissue staining (HPA tissue IHC) | |
| Staining pattern | Cytoplasmic staining, most abundant in glandular cells (HPA tissue IHC) | |
| Antigen retrieval | Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen) | |
| Positive control | Pancreas+4 more · see all | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across paraffin sections. (standard IHC practice; not target-specific) | |
| Caveat | Antibody staining has low consistency with RNA data (HPA tissue IHC) | |
| Regulation | Highest expression in endocrine glands and testis (UniProt) | |
| Isoform / epitope | 2 isoforms; check epitope coverage for each (UniProt) |
Section 1
Recommended ARFGAP3 IHC & IF Protocols
The catalog antibody’s IHC-P protocol is paired with one published ARFGAP3 anterior vaginal wall IHC study (PMC7774809).
| Sample | Paraffin-embedded mouse stomach tissue; fixative not specified (datasheet A06839-1) |
| Fixation | Image fixative and duration unreported (datasheet A06839-1); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat-induced epitope retrieval in citrate buffer, pH 6.0, 20 min at 95–98 °C (standard rule: cytoplasmic / membrane antigen) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% normal serum of the secondary host, 30 min, room temperature (standard) |
| Primary antibody | Rabbit anti-ARFGAP3, 1:50-1:200 (datasheet A06839-1) |
| Primary incubation | Overnight at 4 °C (standard) |
| Detection | HRP-polymer secondary, DAB chromogen 5–10 min (standard) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | ARFGAP3-positive staining in exocrine glandular cells of pancreas (HPA tissue IHC: Medium). HPA tissue profile: Cytoplasmic expression in several different tissue types, most abundant in glandular cells. No signal in the no-primary control. |
💡Decision noteStart with citrate pH 6.0 retrieval at 95–98 °C for 20 min, consistent with ARFGAP3’s cytoplasmic and Golgi localisation (page retrieval; UniProt Q9NP61).
Section 2
What Is the Expected ARFGAP3 Staining Pattern?
ARFGAP3 should appear primarily in the cytoplasm, with a Golgi component and possible peripheral puncta (HPA subcellular; UniProt Q9NP61 localization). Glandular cells in several tissues show medium IHC staining, including pancreatic exocrine cells and prostate glandular cells (HPA tissue IHC). ARFGAP3 has no transmembrane segment (UniProt Q9NP61 topology). The tissue IHC profile is Approved, although antibody staining and RNA expression have low consistency (HPA tissue IHC).
| Cytoplasmic staining in pancreatic exocrine glandular cells, with a concentrated perinuclear component. | This fits medium staining in those cells (HPA tissue IHC) and the cytosolic and Golgi locations (HPA subcellular). A Golgi-like concentration may be easier to judge in IF; chromogenic IHC can show the broader cytoplasmic pattern without resolving individual structures (general IHC practice). |
| Predominantly nuclear staining, with little cytoplasmic signal in glandular cells. | A nuclear-dominant pattern conflicts with the reported cytosol and Golgi locations (HPA subcellular; UniProt Q9NP61 localization). Treat it as suspect and compare the antibody-stained section with its negative control before assigning ARFGAP3 localization (general IHC practice). |
| Strong staining in adipocytes while the expected glandular-cell pattern is absent. | Adipocytes were not detected in the HPA tissue IHC profile, whereas several glandular-cell populations stained at medium levels (HPA tissue IHC). Consider cross-reactivity or endogenous chromogenic activity; the adipocyte result does not establish that every cell in adipose tissue is negative (general IHC practice; HPA tissue IHC). |
| Broad, fairly even colour across cells and surrounding section, obscuring cell boundaries. | This is less consistent with a cell-associated cytoplasmic pattern (HPA tissue IHC; HPA subcellular). Background from detection reagents or insufficient blocking may obscure a real signal; assess the negative control and background before scoring cells (general IHC practice). |
| No staining in pancreatic exocrine or prostate glandular cells. | Both are medium-staining populations in the HPA tissue IHC profile (HPA tissue IHC). Check tissue integrity, retrieval, antibody and detection controls before calling the sample negative (general IHC practice). An HPA reference pattern is a comparator, not a guarantee for every specimen (HPA tissue IHC). |
💡Expected ARFGAP3 appearanceCall a result positive when glandular cells show discernible, approximately medium cytoplasmic staining, potentially concentrated near the Golgi (HPA tissue IHC; HPA subcellular); nuclear-dominant or cell-independent diffuse colour is suspect (HPA subcellular; general IHC practice).
| Cellular location and topology | ARFGAP3 is reported at the Golgi membrane, in cytoplasm and on peripheral puncta likely associated with the ER–Golgi intermediate compartment; it has no transmembrane segment (UniProt Q9NP61 localization and topology). Judge cytoplasmic signal in context rather than requiring a crisp membrane outline (general IHC practice). |
| Tissue and cell selection | Pancreatic exocrine, prostate, salivary, rectal, stomach and small-intestinal glandular cells show medium staining, as do placental decidual cells and seminal-vesicle glandular cells (HPA tissue IHC). Choose an annotated cell population as the positive comparator; adjacent cells need not stain equally (general IHC practice). |
| Strength of tissue evidence | The tissue IHC profile is Approved but notes low consistency between antibody staining and RNA expression; RNA specificity is low (HPA tissue IHC). Use the observed cell pattern as a reference and interpret an unexpected result with controls, without treating RNA abundance as an exact IHC intensity prediction (general IHC practice). |
| Antibody validation | HPA000638 is Approved for IHC and Supported for ICC (HPA antibodies). These application labels describe the supplied antibody validation; they do not validate every staining condition or resolve an unexpected result in a new specimen (HPA antibodies; general IHC practice). |
| IF/ICC Q: What location should fluorescence show? | A: Mainly cytosol, with an additional Golgi signal (HPA subcellular). HPA lists ICC-IF images in A-431, U-251MG and U2OS cells (HPA subcellular). IF/ICC conditions belong to its separate guide; this location summary does not specify an IF protocol. |
| Situation | Likely cause | Next action |
|---|---|---|
| The positive-comparator glandular cells have no visible signal. | The tissue may have inadequate antigen exposure, or the antibody or chromogenic detection step may have failed (general IHC practice). Pancreatic exocrine and prostate glandular cells are medium-staining HPA comparators (HPA tissue IHC). | Confirm the annotated cell population is present, inspect a positive control, and check the established retrieval and detection workflow (general IHC practice). Do not infer target-specific fixation sensitivity; none is supplied. |
| Nearly every structure develops diffuse chromogen. | Broad staining is difficult to reconcile with the reported cytoplasmic cell pattern (HPA tissue IHC; HPA subcellular). Detection background, incomplete blocking or inadequate washing can cause diffuse colour (general IHC practice). | Review the negative control, blocking, washing and detection steps; score ARFGAP3 only where cell-associated signal remains distinguishable from background (general IHC practice). |
| The main signal appears nuclear. | Neither HPA nor UniProt lists the nucleus as an ARFGAP3 location in the supplied records (HPA subcellular; UniProt Q9NP61 localization). Nuclear colour may reflect nonspecific staining or a detection artefact (general IHC practice). | Compare with the negative control and a positive tissue showing the expected cytoplasmic pattern before interpreting nuclear colour as ARFGAP3 (HPA tissue IHC; general IHC practice). |
| Unexpected cells stain strongly while annotated glandular cells are weak. | The HPA reference includes medium glandular-cell staining but also records cell populations with low or undetected staining (HPA tissue IHC). Cross-reactivity or endogenous detection activity is possible (general IHC practice). | Check the exact cell annotation, compare positive and negative controls, and assess endogenous chromogenic activity with the appropriate detection control (HPA tissue IHC; general IHC practice). |
| A positive section looks weaker than another tissue or run. | HPA assigns medium staining to several specified populations, not a fixed intensity for every specimen (HPA tissue IHC). Section quality and staining conditions can change apparent intensity (general IHC practice). | Compare equivalent cell populations under the same scoring criteria, then review section quality and run controls before changing the interpretation (general IHC practice). |
| Fine Golgi or peripheral puncta are hard to distinguish in chromogenic IHC. | UniProt reports Golgi membrane and peripheral punctate localization, while HPA reports a mainly cytosolic ICC-IF signal with an additional Golgi signal (UniProt Q9NP61 localization; HPA subcellular). Fine structures may be unresolved in tissue IHC (general IHC practice). | Assess the broader cytoplasmic glandular-cell pattern against the HPA tissue reference; use the separate IF/ICC guide if the subcellular distribution itself must be resolved (HPA tissue IHC; general IHC practice). |
Experiment evidence
IHC & IF images showing ARFGAP3 staining
A06839-1 · IHCImmunohistochemistry of paraffin-embedded mouse stomach using ARFGAP3 antibody at dilution of 1:100 (x40 lens).
A06839-1 · IHCImmunohistochemistry of paraffin-embedded human liver cancer using ARFGAP3 antibody at dilution of 1:100 (x40 lens).
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000242247-ARFGAP3/tissue/cerebral+cortex#imid_226722
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000242247-ARFGAP3/tissue/colon#imid_226656
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000242247-ARFGAP3/tissue/liver#imid_226657
HPA · PancreasHuman Protein Atlas IHC, Pancreas. Source: https://www.proteinatlas.org/ENSG00000242247-ARFGAP3/tissue/pancreas#imid_226616
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA000638; green = ARFGAP3, blue = nucleus, red = microtubules.
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA000638; green = ARFGAP3, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for ARFGAP3 IHC & IF
🧪Run pancreas first and expect staining in exocrine glandular cells (HPA: Medium in pancreatic exocrine glandular cells). Use adipose tissue as the negative comparator, where adipocytes are listed as not detected (HPA: Not detected in adipocytes); neighboring cells on the pancreas slide should show background only if independently confirmed to lack ARFGAP3.
Positive control tissue: Pancreas (Exocrine glandular cells, HPA Medium)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show ARFGAP3 in A-431, U-251MG, U2OS, with annotated localisation: Cytosol (supported) (HPA subcellular).
Technical controls: Include a no-primary (secondary-only) control and an isotype control matched to the primary antibody’s host species, clonality and concentration. Use ARFGAP3 knockout material as a biological specificity control where available, and quench endogenous peroxidase before chromogenic detection while checking the pancreas control slide for residual background (standard IHC practice).
⚠️Feasibility: A target-specific fixation window and the effect of antigen retrieval are unreported in the supplied evidence; optimize retrieval with the IHC-validated antibody using a small pilot series. The selected A06839-1 caption shows paraffin-section mouse stomach staining at 1:100 but leaves the fixative unreported (selected tissue-IHC caption). Frozen-section staining cannot be assumed easier; ICC-IF images support cytosolic and additional Golgi localization in A-431, U-251MG and U2OS cells, while pancreatic background should be assessed with the control slide (HPA: subcellular localization; standard IHC practice).
HPA tissue IHC evidence for ARFGAP3
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — Low consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Pancreas | Exocrine glandular cells | Medium | Protein (IHC) | HPA → |
| Placenta | Decidual cells | Medium | Protein (IHC) | HPA → |
| Prostate | Glandular cells | Medium | Protein (IHC) | HPA → |
| Rectum | Glandular cells | Medium | Protein (IHC) | HPA → |
| Salivary gland | Glandular cells | Medium | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Caudate | Glial cells | Not detected | Protein (IHC) | HPA → |
| Cerebellum | Cells in granular layer | Not detected | Protein (IHC) | HPA → |
| Cerebral cortex | Endothelial cells | Not detected | Protein (IHC) | HPA → |
| Cervix | Glandular cells | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced ARFGAP3 IHC Tips
Troubleshoot ARFGAP3 staining in paraffin sections by checking retrieval, controls and whether the signal fits its reported cytosolic and Golgi localisation.
Which retrieval conditions should I try first for weak ARFGAP3 staining?
Start with citrate buffer at pH 6.0, heated to 95–98 °C for 20 min (page retrieval rule). Apply the same heating, cooling and staining schedule to test and control sections so any difference can be interpreted as a staining difference (standard IHC practice). If staining remains weak, test a longer or shorter retrieval time on matched sections before changing buffer, while checking whether tissue structure is preserved (standard IHC practice). A paraffin mouse stomach image was obtained with antibody A06839-1 at 1:100, but its caption does not report retrieval conditions (caption A06839-1).
How should I troubleshoot fixation-related loss of ARFGAP3 staining?
ARFGAP3-specific sensitivity to fixation is unknown from the supplied evidence; the mouse stomach caption identifies paraffin embedding but does not state a fixative (caption A06839-1). Record the fixative, time in fixative and processing schedule for each specimen, then compare sections processed together with the same citrate pH 6.0 retrieval (page retrieval rule; standard IHC practice). If a weak result tracks with a processing batch, compare that batch against a previously staining control before changing antibody concentration (standard IHC practice). Do not infer a fixation effect from the reported cytosolic and Golgi localisation or phosphorylation sites alone (UniProt Q9NP61; HPA subcellular).
What staining pattern is plausible for ARFGAP3 in a paraffin section?
Look primarily for cytoplasmic staining, allowing a more concentrated perinuclear Golgi pattern where section quality and chromogenic resolution permit (HPA tissue IHC; HPA subcellular). ARFGAP3 is reported at the Golgi apparatus membrane, in the cytoplasm and on peripheral puncta thought likely to represent the ER–Golgi intermediate compartment (UniProt Q9NP61). It has no annotated transmembrane segment, so a continuous plasma membrane rim should prompt a specificity check rather than serve as the expected pattern (UniProt Q9NP61 topology). Compare glandular cells within the same section, since cytoplasmic expression is reported across tissues and is most abundant in glandular cells (HPA tissue IHC).
How can isoforms or epitope masking explain discordant ARFGAP3 results?
ARFGAP3 has 2 annotated isoforms, but the supplied antibody caption does not identify the recognised epitope or establish equal recognition of both (UniProt Q9NP61; caption A06839-1). Request the immunogen or epitope sequence and map it against both isoforms before comparing staining across specimens (standard antibody validation practice). The Arf-GAP domain spans residues 10–126, and annotated phosphoserines include positions 231 and 270; neither annotation establishes antibody binding or fixation sensitivity (UniProt Q9NP61). If results disagree between antibodies, compare their documented epitopes and stain adjacent sections under matched retrieval conditions before assigning the difference to isoform expression (standard IHC practice).
How should I use IF to investigate an ambiguous IHC pattern?
Use IF as a follow-up to chromogenic IHC and compare the spatial pattern with the paraffin section result; supported IF localisation is mainly cytosolic with an additional Golgi signal (HPA subcellular). Multiplex ARFGAP3 with a validated marker for the expected glandular cell population, since glandular cells are prominent in tissue IHC observations (HPA tissue IHC; standard IF practice). Choose spectrally separated fluorophores after checking unstained tissue for autofluorescence, and include single-stain controls when comparing channels (standard IF practice). Because ARFGAP3 has no annotated transmembrane segment, select permeabilisation to expose a documented cytosolic or Golgi-facing epitope, and verify access experimentally if epitope orientation is unknown (UniProt Q9NP61 topology; standard IF practice).
What should I adjust when diffuse brown staining obscures ARFGAP3?
First compare a no-primary control with the stained section to locate signal from detection reagents or endogenous tissue activity (standard IHC practice). For a peroxidase and DAB workflow, check the peroxidase block and shorten DAB development if background appears in both sections; these are general workflow adjustments (standard IHC practice). Titrate the primary antibody and strengthen blocking or washes on matched sections if background depends on primary antibody exposure (standard IHC practice). The selected paraffin mouse stomach image used 1:100, which is an image condition rather than evidence that the dilution is optimal for every specimen (caption A06839-1).
How should I quantify ARFGAP3 staining across paraffin sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and cytoplasmic compartment before scoring, because tissue IHC reports cytoplasmic expression most abundantly in glandular cells (HPA tissue IHC). Record the percentage of positive target cells and, when intensity can be scored consistently, calculate an H-score as the sum of each intensity category multiplied by its cell percentage (standard IHC practice). Use one staining batch, exposure or scan settings, and thresholding rule for the comparison; normalise positive counts to the number of eligible cells or their assessed tissue area in mm² (standard IHC practice). Report excluded damaged regions and control-section results alongside each score so background is not counted as ARFGAP3 signal (standard IHC practice).
When is an apparent ARFGAP3-positive signal likely to be artefactual?
A plausible result includes cytoplasmic signal, sometimes concentrated near the Golgi, within an identifiable cell population (HPA tissue IHC; HPA subcellular). Treat an isolated nuclear pattern or a sharp continuous plasma membrane rim cautiously, since neither matches the supplied localisation evidence (UniProt Q9NP61; HPA subcellular). Check whether positivity instead follows section edges, necrotic regions or structures also stained in the no-primary control; those patterns can indicate processing or detection artefacts (standard IHC practice). Tissue IHC reliability is labelled Approved, yet antibody staining and RNA expression show low consistency, so confirm unexpected cell-type assignments with independent evidence before treating them as biological findings (HPA tissue IHC).
Boster reagents
Best ARFGAP3 / ADP-ribosylation factor GTPase-activating protein 3 IHC Antibodies
The anti-ARFGAP3 catalog antibody A06839-1 has real IHC images from paraffin-embedded mouse stomach and human liver cancer; no IF data are provided (A06839-1 image captions; catalog applications).
Real IHC data
Anti-ARFGAP3 Antibody
Cat # A06839-1
A06839-1 lists IHC and Human and Mouse reactivity (catalog applications and reactivity). Its IHC images show paraffin-embedded mouse stomach and human liver cancer, each at 1:100 (A06839-1 image captions).
Which to pick: Choose A06839-1 for tissue IHC in paraffin sections, as shown in its own mouse stomach and human liver cancer images (A06839-1 image captions). It is the listed choice for Human and Mouse samples (catalog reactivity). No IF/ICC choice is supported here because A06839-1 has no listed IF application or IF image; the fixative used for its paraffin sections is unreported (catalog applications; A06839-1 image captions).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q9NP61 (ARFG3_HUMAN, ADP-ribosylation factor GTPase-activating protein 3).
- Human Protein Atlas. ARFGAP3 tissue IHC expression (reliability: Approved).
- Human Protein Atlas. ARFGAP3 subcellular location (ICC-IF): Mainly localized to the cytosol. In addition localized to the Golgi apparatus..
- Human Protein Atlas. ARFGAP3 antibody validation summary (1 antibodies).
- Expression of ArfGAP3 in Vaginal Anterior Wall of Patients With Pelvic Floor Organ Prolapse in Pelvic Organ Prolapse and Non-Pelvic Organ Prolapse Patients. Female pelvic medicine & reconstructive surgery 2021 — PMC7774809.
- PubMed PMID:10704287 — UniProt-cited evidence.
- PubMed PMID:12529303 — UniProt-cited evidence.
- PubMed PMID:15461802 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for ARFGAP3 (ADP-ribosylation factor GTPase-activating protein 3). Expected localisation Cytoplasmic tissue staining (HPA tissue IHC). Antigen retrieval: Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen). Validated IHC antibody: A06839-1 at 1:50-1:200 (the product's own IHC validation image is shown). Controls (HPA): positive Pancreas (Exocrine glandular cells); negative Adipose tissue. IHC workflow; specimen preparation unspecified. Protocol steps: 1. Sample: Paraffin-embedded mouse stomach tissue; fixative not specified (datasheet A06839-1); 2. Fixation: Image fixative and duration unreported (datasheet A06839-1); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat-induced epitope retrieval in citrate buffer, pH 6.0 , 20 min at 95–98 °C…; 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% normal serum of the secondary host, 30 min , room temperature (standard); 8. Primary antibody: Rabbit anti-ARFGAP3, 1:50-1:200 (datasheet A06839-1); 9. Primary incubation: Overnight at 4 °C (standard). Watch for: Fixation: Keep fixation consistent across paraffin sections. (standard IHC practice; not target-specific); Caveat: Antibody staining has low consistency with RNA data (HPA tissue IHC); Isoform / epitope: 2 isoforms; check epitope coverage for each (UniProt); Regulation: Highest expression in endocrine glands and testis (UniProt). Evidence: UniProt Q9NP61, HPA tissue IHC · Approved, HPA ICC-IF · Mainly localized to the cytosol. In addition localized to the Golgi…, Datasheet A06839-1, PMC7774809. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/ARFGAP3/immunohistochemistry-ihc-guide.